Why the study?
Clinical guidelines diverge on circulating biomarkers in HF management, and multiple biomarker approaches remain rare in routine clinical practice despite evidence that novel biomarkers can enhance risk prediction.
Are multiple biomarker models more effective than a single biomarker in improving risk stratification strategies in patients with HF?
Are multiple biomarker models more effective than a single biomarker in improving risk stratification strategies in patients with HF?
While multiple biomarker models improve risk stratification in heart failure beyond natriuretic peptides alone, significant barriers prevent their routine clinical implementation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Berezin et al. (2021) conducted a review in Heart failure. Multiple biomarker models vs. Single biomarker approach was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: